Repligen (RGEN) Competitors $115.06 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$115.05 -0.01 (-0.01%) As of 05/22/2026 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RGEN vs. TECH, A, BIO, DHR, and MTDShould you buy Repligen stock or one of its competitors? MarketBeat compares Repligen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Repligen include Bio-Techne (TECH), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Danaher (DHR), and Mettler-Toledo International (MTD). These companies are all part of the "medical" sector. RGEN vs. TECHRGEN vs. ARGEN vs. BIORGEN vs. DHRRGEN vs. MTDHow does Repligen compare to Bio-Techne?Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership. Is TECH or RGEN more profitable? Bio-Techne has a net margin of 9.05% compared to Repligen's net margin of 6.73%. Bio-Techne's return on equity of 13.57% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Bio-Techne9.05% 13.57% 10.66% Repligen 6.73%4.88%3.48% Which has higher valuation and earnings, TECH or RGEN? Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Techne$1.22B6.19$73.40M$0.6969.87Repligen$763.34M8.50$48.89M$0.90127.84 Does the media favor TECH or RGEN? In the previous week, Repligen had 2 more articles in the media than Bio-Techne. MarketBeat recorded 5 mentions for Repligen and 3 mentions for Bio-Techne. Repligen's average media sentiment score of 0.40 beat Bio-Techne's score of 0.00 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Repligen 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in TECH or RGEN? 99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 0.6% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, TECH or RGEN? Bio-Techne has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Repligen has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Do analysts rate TECH or RGEN? Bio-Techne presently has a consensus price target of $65.92, indicating a potential upside of 36.74%. Repligen has a consensus price target of $166.15, indicating a potential upside of 44.41%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Bio-Techne.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Techne 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.79Repligen 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.87 SummaryRepligen beats Bio-Techne on 9 of the 17 factors compared between the two stocks.How does Repligen compare to Agilent Technologies?Repligen (NASDAQ:RGEN) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation. Which has more volatility & risk, RGEN or A? Repligen has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Do institutionals & insiders have more ownership in RGEN or A? 97.6% of Repligen shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is RGEN or A more profitable? Agilent Technologies has a net margin of 18.26% compared to Repligen's net margin of 6.73%. Agilent Technologies' return on equity of 24.49% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Repligen6.73% 4.88% 3.48% Agilent Technologies 18.26%24.49%12.83% Which has better valuation & earnings, RGEN or A? Agilent Technologies has higher revenue and earnings than Repligen. Agilent Technologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$763.34M8.50$48.89M$0.90127.84Agilent Technologies$6.95B4.68$1.30B$4.5325.39 Do analysts recommend RGEN or A? Repligen currently has a consensus target price of $166.15, indicating a potential upside of 44.41%. Agilent Technologies has a consensus target price of $163.71, indicating a potential upside of 42.35%. Given Repligen's higher probable upside, analysts plainly believe Repligen is more favorable than Agilent Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.87Agilent Technologies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media prefer RGEN or A? In the previous week, Agilent Technologies had 13 more articles in the media than Repligen. MarketBeat recorded 18 mentions for Agilent Technologies and 5 mentions for Repligen. Agilent Technologies' average media sentiment score of 0.51 beat Repligen's score of 0.40 indicating that Agilent Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agilent Technologies 5 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAgilent Technologies beats Repligen on 11 of the 16 factors compared between the two stocks.How does Repligen compare to Bio-Rad Laboratories?Repligen (NASDAQ:RGEN) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment. Which has more volatility and risk, RGEN or BIO? Repligen has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Do analysts recommend RGEN or BIO? Repligen presently has a consensus price target of $166.15, indicating a potential upside of 44.41%. Bio-Rad Laboratories has a consensus price target of $303.33, indicating a potential upside of 5.12%. Given Repligen's stronger consensus rating and higher possible upside, equities analysts plainly believe Repligen is more favorable than Bio-Rad Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.87Bio-Rad Laboratories 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings and valuation, RGEN or BIO? Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$763.34M8.50$48.89M$0.90127.84Bio-Rad Laboratories$2.59B2.98$759.90M$6.0747.54 Is RGEN or BIO more profitable? Repligen has a net margin of 6.73% compared to Bio-Rad Laboratories' net margin of 6.52%. Repligen's return on equity of 4.88% beat Bio-Rad Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Repligen6.73% 4.88% 3.48% Bio-Rad Laboratories 6.52%3.56%2.49% Do institutionals and insiders have more ownership in RGEN or BIO? 97.6% of Repligen shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.6% of Repligen shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer RGEN or BIO? In the previous week, Bio-Rad Laboratories had 1 more articles in the media than Repligen. MarketBeat recorded 6 mentions for Bio-Rad Laboratories and 5 mentions for Repligen. Repligen's average media sentiment score of 0.40 beat Bio-Rad Laboratories' score of -0.07 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bio-Rad Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryRepligen beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.How does Repligen compare to Danaher?Danaher (NYSE:DHR) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation. Do analysts prefer DHR or RGEN? Danaher currently has a consensus price target of $238.65, indicating a potential upside of 38.65%. Repligen has a consensus price target of $166.15, indicating a potential upside of 44.41%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Danaher.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Danaher 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.86Repligen 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.87 Which has better earnings & valuation, DHR or RGEN? Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDanaher$24.57B4.96$3.61B$5.1733.29Repligen$763.34M8.50$48.89M$0.90127.84 Do institutionals & insiders believe in DHR or RGEN? 79.1% of Danaher shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 10.8% of Danaher shares are owned by insiders. Comparatively, 0.6% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is DHR or RGEN more profitable? Danaher has a net margin of 14.89% compared to Repligen's net margin of 6.73%. Danaher's return on equity of 10.91% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Danaher14.89% 10.91% 6.94% Repligen 6.73%4.88%3.48% Which has more volatility and risk, DHR or RGEN? Danaher has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Repligen has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Does the media favor DHR or RGEN? In the previous week, Danaher had 23 more articles in the media than Repligen. MarketBeat recorded 28 mentions for Danaher and 5 mentions for Repligen. Danaher's average media sentiment score of 1.21 beat Repligen's score of 0.40 indicating that Danaher is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Danaher 21 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDanaher beats Repligen on 10 of the 17 factors compared between the two stocks.How does Repligen compare to Mettler-Toledo International?Repligen (NASDAQ:RGEN) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership. Is RGEN or MTD more profitable? Mettler-Toledo International has a net margin of 21.40% compared to Repligen's net margin of 6.73%. Repligen's return on equity of 4.88% beat Mettler-Toledo International's return on equity.Company Net Margins Return on Equity Return on Assets Repligen6.73% 4.88% 3.48% Mettler-Toledo International 21.40%-622.80%24.97% Which has more risk and volatility, RGEN or MTD? Repligen has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Does the media refer more to RGEN or MTD? In the previous week, Repligen had 1 more articles in the media than Mettler-Toledo International. MarketBeat recorded 5 mentions for Repligen and 4 mentions for Mettler-Toledo International. Repligen's average media sentiment score of 0.40 beat Mettler-Toledo International's score of 0.07 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mettler-Toledo International 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend RGEN or MTD? Repligen currently has a consensus price target of $166.15, indicating a potential upside of 44.41%. Mettler-Toledo International has a consensus price target of $1,408.55, indicating a potential upside of 27.51%. Given Repligen's stronger consensus rating and higher probable upside, equities analysts clearly believe Repligen is more favorable than Mettler-Toledo International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.87Mettler-Toledo International 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, RGEN or MTD? Mettler-Toledo International has higher revenue and earnings than Repligen. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$763.34M8.50$48.89M$0.90127.84Mettler-Toledo International$4.03B5.54$869.19M$42.6425.91 Do institutionals and insiders have more ownership in RGEN or MTD? 97.6% of Repligen shares are held by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are held by institutional investors. 0.6% of Repligen shares are held by insiders. Comparatively, 0.7% of Mettler-Toledo International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryRepligen beats Mettler-Toledo International on 10 of the 17 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition ExportMetricRepligenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.49B$3.37B$6.43B$12.32BDividend YieldN/A2.26%2.76%5.28%P/E Ratio127.8518.9121.0125.66Price / Sales8.50329.35615.84111.99Price / Cash33.67125.1743.4956.67Price / Book3.087.0910.377.14Net Income$48.89M$24.45M$3.57B$335.98M7 Day Performance10.42%5.45%6.01%3.56%1 Month Performance-2.16%2.43%3.52%2.54%1 Year Performance-2.62%62.98%34.13%35.05% Repligen Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen3.4972 of 5 stars$115.06flat$166.15+44.4%-2.6%$6.49B$763.34M127.852,000TECHBio-Techne3.444 of 5 stars$47.42-1.9%$66.77+40.8%+3.1%$7.57B$1.22B68.733,100AAgilent Technologies4.8766 of 5 stars$111.73-3.4%$163.71+46.5%+5.9%$32.67B$6.95B24.6618,100Upcoming EarningsDividend AnnouncementBIOBio-Rad Laboratories1.2398 of 5 stars$243.48-4.3%$333.00+36.8%+28.8%$6.81B$2.58B40.117,450Positive NewsAnalyst RevisionDHRDanaher4.748 of 5 stars$166.46-2.7%$240.70+44.6%-6.9%$121.14B$24.57B32.2060,000Positive News Related Companies and Tools Related Companies Bio-Techne Alternatives Agilent Technologies Alternatives Bio-Rad Laboratories Alternatives Danaher Alternatives Mettler-Toledo International Alternatives Revvity Alternatives Thermo Fisher Scientific Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
